FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897323630> ?p ?o ?g. }

• W2897323630 abstract "Artemisinin-based combination therapy (ACT) is the first-line anti-malarial treatment of uncomplicated malaria in most malaria endemic countries, including Tanzania. Unfortunately, there have been reports of artemisinin resistance and ACT failure from South East Asia highlighting the need to monitor therapeutic efficacy of ACT in these countries as recommended by World Health Organization.Open-label single arm studies in mainland Tanzania were conducted in nine sentinel sites in 2011, 2012 and 2015 to assess the efficacy and safety of artemether/lumefantrine (AL) and artesunate/amodiaquine (ASAQ) using 28 days follow-up and dihydroartemisinin/piperaquine (DHAPQ) using 42 days follow-up. Mutations in the propeller domain of the Plasmodium falciparum kelch 13 (k13) gene and amplification of the P. falciparum plasmepsin 2 (pm2) gene, associated with artemisinin and piperaquine (PQ) resistance, were also investigated.Of the 428 patients enrolled, 328 patients provided study endpoint. For AL, the PCR corrected per-protocol analysis showed adequate clinical and parasitological response (ACPR) of 90.3% (n = 28; 95% CI 74.2-98.0) in Kyela 2012, 95.7% (n = 22; 95% CI 78.1-99.0) in Chamwino, 100% in Muheza (n = 29; 95% CI 88.1-100), 100% in Nagaga (n = 39; 95% CI 91.0-100) and Kyela 2015 (n = 60; 95% CI 94.0-100). For ASAQ, PCR corrected ACPR of 98% (n = 49; 95% CI 89.4-99.9) and 100% (n = 25; 95% CI 86.3-100) were observed in 2011 in Ujiji and Kibaha, respectively. For DHAPQ, the ACPR was 100% (n = 71; 95% CI 94.9-100). Of the 235 samples with genetic interpretable results, only 7 (3%) had non-synonymous k13 mutations. None of these are candidate or validated markers of artemisinin resistance and all patients carrying these alleles cleared the parasites on day 3. Of the DHAPQ group, 10% (3/29) of the samples with interpretable results had pm2 multiple copies and none of them was associated with treatment failure.All the tested ACT in mainland Tanzania were highly efficacious and none of validated k13 mutants associated with artemisinin resistance was observed. However, three isolates with multiple copy numbers of pm2 gene associated with PQ resistance among the limited samples tested successfully calls for further investigation. Trial registration Number ACTRN12615000159550. Registered 18th February 2015, https://www.anzctr.org.au/trial/MyTrial.aspx." @default.
• W2897323630 created "2018-10-26" @default.
• W2897323630 creator A5003048627 @default.
• W2897323630 creator A5006913821 @default.
• W2897323630 creator A5010154254 @default.
• W2897323630 creator A5010252244 @default.
• W2897323630 creator A5014087860 @default.
• W2897323630 creator A5015738003 @default.
• W2897323630 creator A5019096760 @default.
• W2897323630 creator A5037803777 @default.
• W2897323630 creator A5040011317 @default.
• W2897323630 creator A5047802528 @default.
• W2897323630 creator A5056509819 @default.
• W2897323630 creator A5063913005 @default.
• W2897323630 creator A5074442267 @default.
• W2897323630 creator A5074874789 @default.
• W2897323630 creator A5090394978 @default.
• W2897323630 date "2018-10-17" @default.
• W2897323630 modified "2023-10-15" @default.
• W2897323630 title "Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania" @default.
• W2897323630 cites W1870326007 @default.
• W2897323630 cites W1980413697 @default.
• W2897323630 cites W2014072357 @default.
• W2897323630 cites W2099330256 @default.
• W2897323630 cites W2107461435 @default.
• W2897323630 cites W2114802419 @default.
• W2897323630 cites W2124634096 @default.
• W2897323630 cites W2130646906 @default.
• W2897323630 cites W2137432389 @default.
• W2897323630 cites W2142060065 @default.
• W2897323630 cites W2151344802 @default.
• W2897323630 cites W2157261068 @default.
• W2897323630 cites W2159536724 @default.
• W2897323630 cites W2161311583 @default.
• W2897323630 cites W2169329132 @default.
• W2897323630 cites W2265380508 @default.
• W2897323630 cites W2344626565 @default.
• W2897323630 cites W2344718652 @default.
• W2897323630 cites W2467259677 @default.
• W2897323630 cites W2515978767 @default.
• W2897323630 cites W2522550673 @default.
• W2897323630 cites W2547042202 @default.
• W2897323630 cites W2547295550 @default.
• W2897323630 cites W2553359142 @default.
• W2897323630 cites W2569387503 @default.
• W2897323630 cites W2608549546 @default.
• W2897323630 cites W2737472839 @default.
• W2897323630 cites W2772765784 @default.
• W2897323630 cites W2788649440 @default.
• W2897323630 doi "https://doi.org/10.1186/s12936-018-2524-x" @default.
• W2897323630 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6192314" @default.
• W2897323630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30333022" @default.
• W2897323630 hasPublicationYear "2018" @default.
• W2897323630 type Work @default.
• W2897323630 sameAs 2897323630 @default.
• W2897323630 citedByCount "37" @default.
• W2897323630 countsByYear W28973236302019 @default.
• W2897323630 countsByYear W28973236302020 @default.
• W2897323630 countsByYear W28973236302021 @default.
• W2897323630 countsByYear W28973236302022 @default.
• W2897323630 countsByYear W28973236302023 @default.
• W2897323630 crossrefType "journal-article" @default.
• W2897323630 hasAuthorship W2897323630A5003048627 @default.
• W2897323630 hasAuthorship W2897323630A5006913821 @default.
• W2897323630 hasAuthorship W2897323630A5010154254 @default.
• W2897323630 hasAuthorship W2897323630A5010252244 @default.
• W2897323630 hasAuthorship W2897323630A5014087860 @default.
• W2897323630 hasAuthorship W2897323630A5015738003 @default.
• W2897323630 hasAuthorship W2897323630A5019096760 @default.
• W2897323630 hasAuthorship W2897323630A5037803777 @default.
• W2897323630 hasAuthorship W2897323630A5040011317 @default.
• W2897323630 hasAuthorship W2897323630A5047802528 @default.
• W2897323630 hasAuthorship W2897323630A5056509819 @default.
• W2897323630 hasAuthorship W2897323630A5063913005 @default.
• W2897323630 hasAuthorship W2897323630A5074442267 @default.
• W2897323630 hasAuthorship W2897323630A5074874789 @default.
• W2897323630 hasAuthorship W2897323630A5090394978 @default.
• W2897323630 hasBestOaLocation W28973236301 @default.
• W2897323630 hasConcept C126322002 @default.
• W2897323630 hasConcept C203014093 @default.
• W2897323630 hasConcept C2776120307 @default.
• W2897323630 hasConcept C2776793103 @default.
• W2897323630 hasConcept C2776999253 @default.
• W2897323630 hasConcept C2777425658 @default.
• W2897323630 hasConcept C2777616469 @default.
• W2897323630 hasConcept C2778048844 @default.
• W2897323630 hasConcept C2778059366 @default.
• W2897323630 hasConcept C2778118209 @default.
• W2897323630 hasConcept C2778371730 @default.
• W2897323630 hasConcept C2778629330 @default.
• W2897323630 hasConcept C2780780316 @default.
• W2897323630 hasConcept C2781160685 @default.
• W2897323630 hasConcept C42972112 @default.
• W2897323630 hasConcept C71924100 @default.
• W2897323630 hasConcept C98274493 @default.
• W2897323630 hasConceptScore W2897323630C126322002 @default.
• W2897323630 hasConceptScore W2897323630C203014093 @default.
• W2897323630 hasConceptScore W2897323630C2776120307 @default.
• W2897323630 hasConceptScore W2897323630C2776793103 @default.
• W2897323630 hasConceptScore W2897323630C2776999253 @default.

• next